Zobrazeno 1 - 10
of 138
pro vyhledávání: '"35"'
Autor:
N Rueth, Karen K. Swenson, M Knaack, Janet Krueger, Barbara Susnik, P Martone, SR Baldinger, Michaela Tsai, Erin Grimm, Tamera J. Lillemoe
Publikováno v:
Cancer Research. 79:P5-10
Background: While breast cancer is rare in women ≤ age 35, patients in this age group are more frequently diagnosed with aggressive cancer subtypes and pathologic germline mutations in cancer susceptibility genes than older patients. Higher recurre
Autor:
Patricia A. Thompson, Michelle Turner, Carolyn Mies, Jules Cohen, Caterina Vacchi-Suzzi, Alison Stopeck, Lea N. Baer, Christina Preece, Christy A. Russell, Rebecca Batiste, Julie Anne L Gemmill
Publikováno v:
Cancer Research. 81:PS5-37
Background: Identifying when to start CDK4/6 inhibitors or use chemotherapy in hormone receptor positive (HR+) metastatic breast cancer (MBC) remains challenging. The 21-gene Oncotype DX Breast Recurrence Score® test is validated to predict chemothe
Autor:
Fanny Leenhardt, Bénédicte Marion, Claudia Muracciole-Bich, Stéphane Pouderoux, Alexandre Evrard, Catherine Perrin, Céline Roques, Litaty Mbatchi, Marie Alexandre, William Jacot, Céline Gongora, Matthieu Gracia, Nelly Firmin
Publikováno v:
Cancer Research. 81:PS5-16
Background: The CDK4/6 inhibitors palbociclib is prescribed in association with hormonal therapy for the management of metastatic breast cancer patients. Like most oral targeted drug, therapeutic drug monitoring may be used for personalize their dosa
Publikováno v:
Cancer Research. 81:PD11-07
Background. High mammographic density decreases sensitivity of both 2D and 3D mammography. Tamoxifen reduces mammographic density thereby potentially increasing screening sensitivity. We tested if low-dose tamoxifen could be used to increase sensitiv
Publikováno v:
Cancer Research. 80:P1-20
Purpose: Recently, some studies confirmed that the surgical margin in patients with breast fibromatosis was not associated with recurrence. Wide tumor-free resection surgery, which used to be the first-line treatment, might not be necessary for all f
Autor:
Celine M. Vachon, Karthik V. Giridhar, Rachel A. Freedman, Fergus J. Couch, Robert W. Mutter, Roberto A. Leon-Ferre, Rafael E. Jimenez, Sadia Choudhery, Tina J. Hieken, John R. Hawse, Kathryn J. Ruddy, Nilay Shah, Lindsey R. Sangaralingham, Stephanie Payne, Judy C. Boughey, Siddhartha Yadav
Publikováno v:
Cancer Research. 80:P4-17
Background: The clinical utility of routine annual mammogram after curative-intent treatment for male breast cancer is uncertain. There is potentially greater value after lumpectomy (as surveillance for ipsilateral recurrence) than mastectomy (as scr
Autor:
Valeria Caceres, H Ursino, Eduardo Gonzalez, D Bequelman, O Sturla, Maria Dolores Mansilla Figueroa, J Cavallero
Publikováno v:
Cancer Research. 80:P6-08
Background: Argentina is a country with inequalities in terms of healthcare, specially in genetics diseases. The lack of knowledge about hereditary cancer, the small number of genetic counselors and the difficulty of access to genetic testing are bar
Publikováno v:
Cancer Research. 81:2771-2771
In recent years, novel immunotherapy strategies have shown remarkable results in treating various advanced cancers. The efficacy of immunotherapeutics has been dictated by the dynamic and spatially heterogeneous tumor microenvironment (TME) which inc
Publikováno v:
Cancer Research. 77:P3-13
Breast conservation and primary radiation (BCT) is a widely used treatment for early stage breast cancer patients. Studies report a 20-40 percent re-excision rate to obtain clear margins. Current localization practices include needle, radioactive see
Autor:
Margaret E. Macy, Amit J. Sabnis, Katherine A. Janeway, Neal I. Lindeman, Alanna J. Church, Laura Corson, Susan I. Vear, Daniel A. Weiser, Navin R. Pinto, Samuel L. Volchenboum, Julia Glade-Bender, Jaclyn Schienda, Jonathan A. Nowak, Wenjun Kang, Alma Imamovic-Tuco, Joshua D. Schiffman, AeRang Kim, Catherine Clinton, Theodore W. Laetsch, Danielle K. Manning, Brian D. Crompton, Luke Maese, Rochelle Bagatell, Mark A. Applebaum, Junne Kamihara
Publikováno v:
Cancer Research. 80:A06-A06
Introduction: Tumor profiling is becoming a more routine part of clinical care. Many academic centers and commercial entities offer tumor sequencing of cancer-related genes without matched germline profiling. We hypothesize that tumor-only sequencing